The stock price has increased nearly 30 times in one year. These big-selling employees are going to get rich...

The stock price increased nearly 30 times in one year , and nearly 300 employees of Intech Medical were happy

The surge in Intech Medical's stock price is mainly due to the surge in demand for products such as disposable PVC gloves and nitrile gloves during the epidemic .

Matching the surge in market demand is the company’s surging performance.

According to the company's annual report data, the company's operating income in 2020 was 13.837 billion yuan, a year-on-year increase of 564.29%; the net profit attributable to shareholders of listed companies was 7.007 billion yuan, a year-on-year increase of 3,829.56%, significantly higher than in 2019.

The best performing stock in the capital market in 2020 was Innotech Medical, which rose nearly 30 times in one year , its performance increased nearly 6 times, and its net profit increased nearly 40 times.

While the company's performance has grown significantly, Intech Medical has also launched an equity incentive plan to allow the team to share the company's development results and enhance the team's combat effectiveness and cohesion.

In July last year , Yinke Medical issued the "Announcement on the Completion of Registration for Grants of the 2020 Restricted Stock Incentive Plan", announcing the grant status of restricted stocks.

The announcement shows that the incentive plan of Intech Medical has 293 incentive targets , including directors, senior managers and core staff who were employed by the company when the company announced the incentive plan. The number of shares granted is 1.4996 million.

The list of incentive targets and the actual subscription quantity are as follows:

Are they going to get rich overnight? It's not that simple.

According to the announcement, the restricted period for each batch of restricted stocks under this incentive plan is 12 months, 24 months and 36 months respectively from the date of completion of registration of restricted stock grant .

The schedule for lifting the sales restriction period and each period is as follows:

At the same time, corresponding performance must be achieved.

The annual performance evaluation targets for the restricted stocks granted are as follows:

The first period to lift the lock-up period: the company must meet one of the following two conditions: based on the net profit in 2019, the growth rate of net profit in 2020 shall not be less than 100%; based on the operating income in 2019, the growth rate of operating income in 2020 shall not be less than 100%.

The second period to lift the lock-up period: the company must meet one of the following two conditions: based on the 2019 net profit, the net profit growth rate in 2021 is not less than 150%; based on the 2019 operating income, the operating income growth rate in 2021 is not less than 150%.

The third period to lift the lock-up period: the company must meet one of the following two conditions: based on the 2019 net profit, the net profit growth rate in 2022 shall not be less than 220%; based on the 2019 operating income, the operating income growth rate in 2022 shall not be less than 220%.

If Yinke Medical fails to meet the above-mentioned performance evaluation targets, the restricted shares of all incentive targets that can be unblocked in the corresponding evaluation year shall not be unblocked.

However, judging from its performance in 2020 and the current development of the global epidemic, it is not difficult for Intech Medical to successfully complete its performance assessment.

Loctek grants 1.9 million stock options to 89 employees

Recently, Lechuang announced its 2020 annual report. During the reporting period, the company achieved operating income of 1.941 billion yuan , an increase of 98.42% over the same period last year; net profit attributable to shareholders of listed companies was 217 million yuan , an increase of 244.7% over the same period last year .

While its performance soared, Lechuang also announced the " 2020 Stock Option Incentive Plan Implementation Assessment Management Measures Equity Incentive Plan " in June 2020 .

It is reported that Lechuang plans to grant 1.9 million stock options (accounting for 2.17% of the total share capital) to 89 incentive targets including directors, senior managers, middle-level managers and core technical (business) personnel , with an exercise price of 28.75 yuan per share.

The stock options under this incentive plan will be assessed in the three fiscal years of 2020-2022, with one assessment per year.
Second-rate.

The performance evaluation target for each year is: based on the net profit attributable to the parent company after deducting non-recurring items after excluding the impact of equity incentives in 2019, the growth rate of net profit attributable to the parent company after deducting non-recurring items after excluding the impact of equity incentives in 2020, 2021, and 2022 shall not be less than 30%, 70%, and 100%, that is, the net profit attributable to the parent company after deducting non-recurring items shall not be less than 63.65 million, 83.24 million, and 97.93 million. Compared with the company's 2018 restricted stock incentive plan, the evaluation indicator of this incentive plan has changed from revenue to profit, and the company is more concerned about profit growth at this stage.

Nearly 200 employees are going to get rich, Daotong Technology rewards nearly 10 million shares

As a big seller, it is not new to give stocks to employees. As cross-border e-commerce has doubled its profits this year, Daotong Technology, a big seller on Amazon, has also started to spend money to reward employees. The 2020 annual report shows that the main business of Daotong Technology is the automotive electronics industry , accounting for 99.0% of its revenue .

In March of this year , Daotong Technology granted 1.97 million restricted shares to 76 incentive targets at a price of 27 yuan per share. The amount of equity incentive this time is a bit small, but as early as the second half of 2020, Daotong Technology had awarded nearly 10 million shares to its employees.

Daotong Technology granted as many as 9.97 million shares , with the grant price of restricted shares being 27 yuan per share. A total of 137 incentive targets can obtain the shares. Now the share price has reached 74.3 yuan. For employees participating in the incentive plan, the emergence of the equity incentive plan is very promising. It seems that if employees can follow the right company, the future is still promising.

In the first three months of this year , Daotong Technology also performed very strongly. The first quarter report of 2021 showed that during the reporting period, Daotong Technology achieved operating income of 453 million yuan, a year-on-year increase of 62.07%; net profit attributable to shareholders of listed companies was 110 million yuan, a year-on-year increase of 78.51%.

However, this plan also has assessment targets. This reward is divided into four vesting periods: it is planned to assess the company's financial performance indicators on an annual basis in the four fiscal years from 2020 to 2023, with an assessment each fiscal year, so as to achieve the company's financial performance assessment targets as the vesting conditions for the incentive objects in the corresponding years.

The first vesting period is 2020. An operating income increase of 50% or a gross profit increase of 50% compared to 2019 is A; an operating income increase of 30% or a gross profit increase of 30% compared to 2019 is B+.

The second vesting period is 2021. If the operating income increases by 125% compared to 2019 or the gross profit increases by 125% compared to 2019, it is A; if the operating income increases by 69% compared to 2019 or the gross profit increases by 69% compared to 2019, it is B+.

The third vesting period is 2022. If the operating income increases by 238% compared to 2019 or the gross profit increases by 238% compared to 2019, it is A; if the operating income increases by 120% compared to 2019 or the gross profit increases by 120% compared to 2019, it is B+.

The fourth vesting period is 2023, and the operating income increases by 406% or the gross profit increases by 406% compared with 2019 for A; the operating income increases by 186% or the gross profit increases by 186% compared with 2019 for B+.

Not only does the company have growth goals, but individuals also have growth goals. It seems that if you want to get stocks, you still have to work hard and grow quickly with the company.

Youkeshu's parent company gives allowances to directors

After Youkeshu's parent company Tianze Information released its financial report last year, it also released a salary plan, which mentioned that Tianze Information implements an allowance system for independent directors, and the 2021 allowance standard is 120,000 yuan/year (tax included).

The company's external directors (referring to non-independent directors who do not hold other positions in the company) implement an allowance system, and the standard allowance for 2021 is 120,000 yuan/year (including tax); the company's internal directors (excluding independent directors and external directors) receive remuneration performance according to their positions in the company and do not receive additional director allowances. Non-employee representative supervisors receive supervisor allowances, and the standard allowance for 2021 is 120,000 yuan/year (including tax);

For example, the compensation package for senior executives is a combination of base salary and performance-based salary.